What is the Synthesis Scheme Patent for Berotralstat?
The synthesis scheme patent for berotralstat, also known by its brand name Orladeyo, covers the chemical process used to manufacture the drug. These patents are crucial for protecting the methods by which a pharmaceutical compound is made, offering a layer of intellectual property protection separate from patents on the drug itself [1].
When Do Berotralstat's Synthesis Patents Expire?
Details regarding the specific expiration dates of berotralstat's synthesis scheme patents are not publicly available in the provided information. Patent expiration timelines are critical for understanding when generic or biosimilar versions of a drug may enter the market [2]. DrugPatentWatch.com offers resources for tracking such patent information [1].
Why are Synthesis Patents Important for Drugs Like Berotralstat?
Synthesis patents protect the specific chemical routes and manufacturing processes developed by the innovator company. This prevents competitors from using the same, or a very similar, method to produce the drug, even if the composition of matter patent has expired or is challenged [3]. For berotralstat, which is used to treat hereditary angioedema (HAE), safeguarding its manufacturing process ensures the company that invested in its development maintains market exclusivity for a defined period [1][4].
How Does Berotralstat Work to Treat Hereditary Angioedema?
Berotralstat is a plasma kallikrein inhibitor. By blocking plasma kallikrein, it prevents the overproduction of bradykinin, a substance that causes the swelling characteristic of HAE attacks [4]. This mechanism of action is distinct from the drug's manufacturing process but is the basis for its therapeutic effect [4].
What are the Potential Challenges to Berotralstat's Patents?
Pharmaceutical patents, including those covering synthesis schemes, can be subject to legal challenges. Competitors may attempt to invalidate existing patents or argue that their own synthesis methods do not infringe upon them. Such challenges can significantly impact market exclusivity and the introduction of generic alternatives [2]. Information on specific litigation or challenges related to berotralstat's synthesis patents is not provided.
Who Developed Berotralstat?
BioCryst Pharmaceuticals developed berotralstat [4]. The company's efforts in research, development, and patenting are key to its commercial strategy for the drug [1].